Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 4Small Cell Lung Carcinoma 2Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Oligodendroglioma 1Malignant Solid Tumor 1Glioblastoma 1Carcinoma 1Brain Neoplasms 1Astrocytoma 1Advanced Cancer 1

Interventions

Temozolomide 45Radiotherapy 16Carboplatin 15Irinotecan 12Carmustine 12Bevacizumab 12Filgrastim 10Vincristine 9Surgical Procedures, Operative 9Magnetic Resonance Spectroscopy 9Procarbazine 7Peripheral Blood Stem Cell Transplantation 6Imatinib Mesylate 6Erlotinib Hydrochloride 6temsirolimus 5sargramostim 5O(6)-benzylguanine 5Lomustine 5Flucytosine 5Etoposide 5Thiotepa 4Sirolimus 4Cyclophosphamide 4aldesleukin 3Thalidomide 3Surveys and Questionnaires 3Sunitinib 3Radiotherapy, Intensity-Modulated 3Radiation 3Polymerase Chain Reaction 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Oligodendroglioma × etirinotecan pegol × Clear all
NCT01663012 2016-02-24

Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma

Stanford University

Phase 2 Completed
20 enrolled 10 charts
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡